Landiolol study for mitral valve surgery patients
Treatments studied
Part of Heart & circulation clinical trials.
This trial tests a short-acting beta-blocker called Landiolol given during mitral valve surgery to see if it helps the heart recover after surgery. It is for patients who have certain signs of heart strain before their operation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You are scheduled for mitral valve repair or replacement surgery using a heart-lung machine.
- Before surgery, tests show your heart is enlarged or pumping less effectively than normal.
- You do not have severe kidney, liver, or heart rhythm problems, or other serious health issues listed in the full criteria.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adjusting heart failure medications after a valve repair can help people with heart failure and a weak heart pump. It aims to find the best treatment plan to improve outcomes.
This trial tests a short-acting medicine called landiolol to see if it can prevent dangerously fast heart rates during and after major surgery. It is for people who have heart risks and are having a planned non-cardiac surgery.
This trial tests whether landiolol (a short-acting heart-rate–lowering medicine) can reduce deaths compared with standard care in people in septic shock who have a fast heart rate and strong heart pumping. It is meant for a very specific type of critically ill patient while they are on a breathing machine.
This Phase 3 trial tests whether landiolol (a short-acting heart-rate–lowering medicine) can improve blood circulation in adults with septic shock whose heart rate is too fast. Doctors will also check that the medication is safe in this critical-care setting.
This trial focuses on people with severe mitral valve narrowing or leaking who still have symptoms even after the best usual medications. It may help find better care and measure health outcomes when surgery is judged too risky or not suitable.
This trial studies an “epicardial” device placed during planned heart surgery to reduce mitral valve leaking (“mitral regurgitation”). If you have moderate-to-severe valve leak from ischemic heart disease and are already scheduled for heart surgery, this may help improve how well the valve works.
Hear when a new Cardiac Failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.